Nls Pharmaceutics Ag Stock Debt To Equity
| NLSP Stock | USD 3.43 0.06 1.78% |
NLS Pharmaceutics AG fundamentals help investors to digest information that contributes to NLS Pharmaceutics' financial success or failures. It also enables traders to predict the movement of NLS Stock. The fundamental analysis module provides a way to measure NLS Pharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NLS Pharmaceutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | (0.18) | (0.17) |
NLS | Debt To Equity |
NLS Pharmaceutics AG Company Debt To Equity Analysis
NLS Pharmaceutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current NLS Pharmaceutics Debt To Equity | -0.17 |
Most of NLS Pharmaceutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NLS Pharmaceutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NLS Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for NLS Pharmaceutics is extremely important. It helps to project a fair market value of NLS Stock properly, considering its historical fundamentals such as Debt To Equity. Since NLS Pharmaceutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NLS Pharmaceutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NLS Pharmaceutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
NLS Total Stockholder Equity
Total Stockholder Equity |
|
NLS Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NLS Pharmaceutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NLS Pharmaceutics could also be used in its relative valuation, which is a method of valuing NLS Pharmaceutics by comparing valuation metrics of similar companies.NLS Pharmaceutics is currently under evaluation in debt to equity category among its peers.
NLS Pharmaceutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of NLS Pharmaceutics from analyzing NLS Pharmaceutics' financial statements. These drivers represent accounts that assess NLS Pharmaceutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NLS Pharmaceutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 557.1M | 654.8M | 1.0B | 897.9M | 1.1B | |
| Enterprise Value | 1.3B | 559.1M | 649.4M | 1.0B | 898.6M | 1.1B |
NLS Pharmaceutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NLS Pharmaceutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NLS Pharmaceutics' managers, analysts, and investors.Environmental | Governance | Social |
NLS Fundamentals
| Return On Equity | -8.63 | ||||
| Return On Asset | -2.28 | ||||
| Current Valuation | 14.25 M | ||||
| Shares Outstanding | 3.82 M | ||||
| Shares Owned By Insiders | 28.29 % | ||||
| Shares Owned By Institutions | 12.05 % | ||||
| Number Of Shares Shorted | 22.55 K | ||||
| Price To Book | 4.84 X | ||||
| EBITDA | (11.8 M) | ||||
| Net Income | (12.17 M) | ||||
| Cash And Equivalents | 1.35 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.63 M | ||||
| Current Ratio | 0.59 X | ||||
| Book Value Per Share | (9.40) X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Short Ratio | 0.83 X | ||||
| Earnings Per Share | (6.74) X | ||||
| Target Price | 6.0 | ||||
| Beta | -0.52 | ||||
| Market Capitalization | 13.09 M | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (70.37 M) | ||||
| Working Capital | (6.1 M) | ||||
| Net Asset | 1.85 M |
About NLS Pharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NLS Pharmaceutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NLS Pharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NLS Pharmaceutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NLS Pharmaceutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.Moving together with NLS Stock
| 0.78 | ME | 23Andme Holding | PairCorr |
| 0.85 | VALN | Valneva SE ADR | PairCorr |
| 0.72 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against NLS Stock
| 0.51 | KZR | Kezar Life Sciences | PairCorr |
| 0.48 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.41 | NXGLW | NexGel Warrant | PairCorr |
| 0.4 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.39 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.